About Bio Sequence
Bio Sequence is a company based in Paterna (Spain) founded in 2012 was acquired by OncoDNA in February 2017. Bio Sequence offers products and services including OncoDEEP, OncoSELECT, OncoFOLLOW, and Prosigna. Bio Sequence operates in a competitive market with competitors including Guardant Health, Denali Therapeutics, Foundation Medicine, ArcherDX and MiRagen, among others.
- Headquarter Paterna, Spain
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biosequence S.L.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Bio Sequence
Bio Sequence offers a comprehensive portfolio of products and services, including OncoDEEP, OncoSELECT, OncoFOLLOW, and Prosigna.
Analyzes DNA, RNA, and proteins in solid biopsies for tumor insights.
Sequences genes to detect alterations in advanced tumors.
Tracks tumor mutations via liquid biopsy for treatment response.
Classifies breast cancer subtypes for prognosis and therapy.
Funding Insights of Bio Sequence
Detailed funding history for Bio Sequence
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Bio Sequence
Bio Sequence has secured backing from 1 investor. Prominent investors backing the company include OncoDNA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Genomic and theranostic services for oncology precision medicine are delivered.
|
Locked | Locked | Locked |
Investor details for Bio Sequence
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bio Sequence
Investment portfolio details for Bio Sequence
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Bio Sequence
Detailed financials for Bio Sequence
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bio Sequence Comparisons
Peer comparison for Bio Sequence
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bio Sequence
Bio Sequence operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Denali Therapeutics, Foundation Medicine, ArcherDX and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
Detailed competitors of Bio Sequence
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bio Sequence
Complete news archive for Bio Sequence
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bio Sequence
Bio Sequence was founded in 2012.
Bio Sequence is headquartered in Paterna, Spain. It is registered at Paterna, Valencian Community, Spain.
Bio Sequence was founded in 2012 in Paterna, Spain, within the biotechnology sector. Diagnosis solutions for precision medicine and cancer treatment are developed, with genetic studies provided to personalize options for patients. The product lineup includes OncoDEEP, OncoSELECT, and OncoFOLLOW, supporting targeted therapies through molecular analysis. Operations emphasize clinical diagnostics in oncology.
Bio Sequence's top competitors include Guardant Health, Strand Life Sciences and Juno Therapeutics.
Bio Sequence offers OncoDEEP, OncoSELECT, OncoFOLLOW, and Prosigna.
Bio Sequence has 1 investor. Key investors include OncoDNA.